NumFin

G1 Therapeutics, Inc.

符号: GTHX

NASDAQ

4.44

USD

今天的市场价格

  • -7.4160

    市盈率

  • -0.3307

    PEG比率

  • 232.23M

    MRK市值

  • 0.00%

    DIV收益率

G1 Therapeutics, Inc. (GTHX) 财务报表

Download
年度季度
线性对数
在图表中，您可以看到 的动态默认数字 G1 Therapeutics, Inc. (GTHX). 的默认数据。公司收入显示 21.214 M 的平均值，即 -0.051 % 增长率。整个期间的平均毛利润为 19.38 M，即 11.744 %. 平均毛利率为 0.096 %. 公司去年的净收入增长率为 -0.675 %，等于 -0.344 % % 整个公司历史的平均增长率.,

年度季度
10Y20Y30Y40Y

资产负债表

深入分析 G1 Therapeutics, Inc. 的财务轨迹，我们可以看到其平均资产增长率。有趣的是，这一增长率为 ，反映了公司的高点和低点。与季度相比，这一数字调整为0. 回顾过去一年，总资产变化为 -0.353. 在流动资产领域，GTHX 的报告货币为114.948. 这些资产中的很大一部分，即 82.219 是现金和短期投资。与去年的数据相比，该部分的变化率为-0.433%. 公司的长期投资虽然不是其重点，但以报告货币计算的0.187（如果有的话）为0.187。这表明与上一报告期相比，-25.200% 的差异反映了公司的战略转变. 公司的债务概况显示，以报告货币计算的长期债务总额为 51.557. 这一数字表明，-0.317% 的年同比变化. 股东权益总额所体现的股东价值是以报告货币计算的 35.386. 这方面的年同比变化率为 -0.485%. 深入了解公司财务信息后，会发现更多细节。应收账款净额的估值为12.687，存货估值为 12.44，商誉估值为 0（如有. 无形资产总额（如果有）按 0 估值. 应付账款和短期债务分别为 3.99 和 1.28. 债务总额为57.17，债务净额为 24.89. 其他流动负债为 23.83，加上总负债 86.15. 最后，如果存在推荐股票，则其估值为 0.

common:word.in-mln

USD
Growth
TTM2023202220212020201920182017201620152014

balance-sheet.row.cash-and-short-term-investments

345.9982.2145.1221.2
207.3
269.2
369.3
103.8
47.3
22.9
3.7

balance-sheet.row.short-term-investments

185.2849.950.50
0
0
0
0
0
0
0

balance-sheet.row.net-receivables

46.7812.711.15.7
0.2
0
0
0
0
0
0

balance-sheet.row.inventory

54.0812.416.23.5
0
0
0
0
0
0
0

balance-sheet.row.other-current-assets

30.427.67.113.2
8.8
1.8
0.8
0.8
0.6
0.8
0

balance-sheet.row.total-current-assets

477.33114.9179.5243.6
216.4
271
370.1
104.7
47.9
23.7
3.7

balance-sheet.row.property-plant-equipment-net

26.326.489
10.5
13.4
1.1
0.5
0.3
0.1
0.1

balance-sheet.row.goodwill

0000
0
0
0
0
0
0
0

balance-sheet.row.intangible-assets

0000
0
0
0
0
0
0
0

balance-sheet.row.goodwill-and-intangible-assets

0000
0
0
0
0
0
0
0

balance-sheet.row.long-term-investments

0.620.20.30.3
0.4
0.4
0
0
0
0
0

balance-sheet.row.tax-assets

0000
0
0
0
0
0
0
0

balance-sheet.row.other-non-current-assets

0.2800.31.2
1.2
0
0
0
0
0
-0.1

balance-sheet.row.total-non-current-assets

27.236.68.510.5
12.2
13.8
1.1
0.5
0.3
0.1
0.1

balance-sheet.row.other-assets

0000
0
0
0
0
0
0
0

balance-sheet.row.total-assets

504.55121.5188254.1
228.6
284.8
371.3
105.2
48.2
23.9
3.8

balance-sheet.row.account-payables

22.247.42.9
3.6
3.7
3.4
4.2
2.6
1.1
0.3

balance-sheet.row.short-term-debt

31.91.31.11.1
16.5
0.7
0
0
0
0
0

balance-sheet.row.tax-payables

0000
0
0
0
0
0
0
0

balance-sheet.row.long-term-debt-total

116.1651.682.681.9
27.8
9.5
0
0
0
0
0

Deferred Revenue Non Current

20.511
0
0
0
0
0
0
0

balance-sheet.row.deferred-tax-liabilities-non-current

-46.6---
-
-
-
-
-
-
-

balance-sheet.row.other-current-liab

73.9423.82723.6
3.1
15.4
9
7.5
3
1
0.1

balance-sheet.row.total-non-current-liabilities

210.9756.483.682.9
27.8
9.5
0.1
0.1
0
0
0

balance-sheet.row.other-liabilities

0000
0
0
0
0
0
0
0

balance-sheet.row.capital-lease-obligations

18.014.36.87.9
7.9
10.2
0
0
0
0
0

balance-sheet.row.total-liab

340.8686.2119.2110.6
51.2
29.3
12.4
11.8
5.6
2.2
0.3

balance-sheet.row.preferred-stock

0000
0
0
0
0
107.6
53.4
14.1

balance-sheet.row.common-stock

0.02000
0
0
0
0
0
0
0

balance-sheet.row.retained-earnings

-3090.2-780-732-584.5
-436.1
-336.9
-214.4
-129.1
-65
-31.7
-10.6

balance-sheet.row.accumulated-other-comprehensive-income-loss

0000
0
0
-0.3
-0.2
-0.1
-0.1
0

balance-sheet.row.other-total-stockholders-equity

2441.74815.4800.80
0
0
0.3
222.7
0.1
0.1
0

balance-sheet.row.total-stockholders-equity

-648.4335.468.7-584.5
-436.1
-336.9
-214.4
93.4
42.6
21.7
3.5

balance-sheet.row.total-liabilities-and-stockholders-equity

-307.57121.5188-473.9
-384.9
-307.5
-202
105.2
48.2
23.9
0

balance-sheet.row.minority-interest

0000
0
0
0
0
0
0
0

balance-sheet.row.total-equity

-648.4335.468.7-584.5
-436.1
-336.9
-214.4
-
-
-
3.5

balance-sheet.row.total-liabilities-and-total-equity

-307.57---
-
-
-
-
-
-
-

Total Investments

185.4750.150.50.3
0.4
0.4
0
0
0
0
0

balance-sheet.row.total-debt

127.7257.283.883.1
27.8
10.2
0
0
0
0
0

balance-sheet.row.net-debt

-74.7124.9-10.8-138.1
-179.5
-259
-369.3
-103.8
-47.3
-22.9
-3.7

现金流量表

在 G1 Therapeutics, Inc. 的财务状况中，自由现金流在过去一段时间内发生了显著变化，呈现出 0.703 的转变。该公司最近通过发行 -0.22 扩大了股本，与上一年相比出现了0.000 的差异. 公司的投资活动产生了现金使用净额，按报告货币计算达到2810000.000. 与上一年相比， -1.056 发生了变化. 在同一时期，公司记录了 0.51, 0 和 -26.69，这对于了解公司的投资和还款策略具有重要意义. 公司的融资活动导致使用的现金净额为0.000，同比差异为0.000. 此外，公司还将0 用于向股东分红。与此同时，该公司还采取了其他财务措施，即 -0.28，这也对其在此期间的现金流产生了重大影响. 这些组成部分合在一起，全面反映了公司的财务状况和现金流管理的战略方针。

common:word.in-mln

USD
Growth
TTM2023202220212020201920182017201620152014

cash-flows.row.net-income

-30.59-48-147.6-148.4
-99.3
-122.4
-85.3
-60.1
-30.3
-20.3
-6.7

cash-flows.row.depreciation-and-amortization

0.50.50.50.5
0.6
0.4
0.2
0.1
0.1
0
0

cash-flows.row.deferred-income-tax

01.200.6
-0.5
-16.9
0
0
-1.4
4.9
-0.3

cash-flows.row.stock-based-compensation

10.6714.520.622.3
18.8
16.4
10.2
3.4
1.4
0.4
0.1

cash-flows.row.change-in-working-capital

1.14-5.2-5.3-8.8
-4.1
6.1
0.6
6.1
3.6
0.9
0.2

cash-flows.row.account-receivables

4.37-1.6-5.4-5.5
-0.2
0
0
0
0
0
0.2

cash-flows.row.inventory

33.7-12.7-3.5
-3.8
0
0
0
0
0
0

cash-flows.row.account-payables

-0.37-3.44.4-0.7
-0.2
0.2
-1
6.3
0
0
0

cash-flows.row.other-working-capital

-4.26-48.40.8
0.2
5.8
1.6
-0.3
3.6
0.9
0

cash-flows.row.other-non-cash-items

9.12-1.43.11.7
0.8
16.9
0
0
1.5
0.2
-0.1

cash-flows.row.net-cash-provided-by-operating-activities

-18.18000
0
0
0
0
0
0
0

cash-flows.row.investments-in-property-plant-an-equipment

00-0.50
0
-2.7
-0.7
-0.3
-0.2
-0.1
-0.1

cash-flows.row.acquisitions-net

00500
0.2
0
0
0
0
0
0

cash-flows.row.purchases-of-investments

-116.81-124.7-650
0
0
0
0
0
0
0

cash-flows.row.sales-maturities-of-investments

122127.5150
0
0
0
0
0
0
0

cash-flows.row.other-investing-activites

-0.10-500
0
0
0
0
0
0
0

cash-flows.row.net-cash-used-for-investing-activites

5.192.8-50.50
0.2
-2.7
-0.7
-0.3
-0.2
-0.1
-0.1

cash-flows.row.debt-repayment

-26.69-26.70-53.6
-19.4
0
0
0
0
0
0

cash-flows.row.common-stock-issued

-0.01-0.252.486.4
2.3
2.7
339.6
108.5
0
0
0

cash-flows.row.common-stock-repurchased

0000
0
0
0
0
0
0
0

cash-flows.row.dividends-paid

0000
0
0
0
0
0
0
0

cash-flows.row.other-financing-activites

-8.76-0.30.1113.1
38.8
2.7
0.9
-1.2
49.8
33.2
6.3

cash-flows.row.net-cash-used-provided-by-financing-activities

-35.42-26.952.5145.9
21.7
2.7
340.5
107.3
49.8
33.2
6.3

cash-flows.row.effect-of-forex-changes-on-cash

00.100
0
0
0
0
0
0
4

cash-flows.row.net-change-in-cash

-48.41-62.4-126.713.8
-61.9
-99.6
265.5
56.5
24.4
19.2
3.7

cash-flows.row.cash-at-end-of-period

161.5232.394.9221.6
207.8
269.7
369.3
103.8
47.3
22.9
3.7

cash-flows.row.cash-at-beginning-of-period

209.9394.7221.6207.8
269.7
369.3
103.8
47.3
22.9
3.7
0

cash-flows.row.operating-cash-flow

-18.18-38.3-128.6-132.1
-83.7
-99.6
-74.3
-50.5
-25.1
-13.8
-6.5

cash-flows.row.capital-expenditure

00-0.50
0
-2.7
-0.7
-0.3
-0.2
-0.1
-0.1

cash-flows.row.free-cash-flow

-18.18-38.3-129.1-132.1
-83.7
-102.3
-75
-50.8
-25.4
-13.9
-6.6

利润表行

G1 Therapeutics, Inc. 的收入与上期相比变化了 0.608%。据报告, GTHX 的毛利润为 75.32。该公司的营业费用为 114.84，与上年相比变化了 -37.494%. 折旧和摊销费用为 0.51，与上一会计期间相比变化了 -0.600%. 营业费用报告为 114.84，显示-37.494% 的同比变化。 销售和营销费用为 0, 其中 0.000% 与上年相比发生了变化。 基于近期数据的EBITDA为 0，同比增长0.710%. 营业收入为 -39.53，与上年相比变化了-0.710%. 净利润的变化率为 -0.675%。去年的净收入为-47.97.

common:word.in-mln

USD
Growth
TTM2023202220212020201920182017201620152014

income-statement-row.row.total-revenue

84.0482.551.331.5
45.3
0
0
0
0
0.5
1

income-statement-row.row.cost-of-revenue

6.827.23.72
0
0.4
0
0
0
0
5

income-statement-row.row.gross-profit

77.2375.347.629.5
45.3
-0.4
0
0
0
0.5
-4

income-statement-row.row.gross-profit-ratio

0000
0
0
0
0
0
0
0

income-statement-row.row.research-development

35.55---
-
-
-
-
-
-
-

income-statement-row.row.selling-general-administrative

0---
-
-
-
-
-
-
-

income-statement-row.row.selling-and-marketing-expenses

0---
-
-
-
-
-
-
-

income-statement-row.row.other-expenses

5.272.20-0.3
-0.5
6.6
4
0.9
0.2
0
0

income-statement-row.row.operating-expenses

102.6114.8183.7171.9
141.8
129
89.3
61
30.4
15.9
2.7

income-statement-row.row.cost-and-expenses

106.34122187.5173.9
141.8
129
89.3
61
30.4
15.9
7.7

income-statement-row.row.interest-income

2.042.50.70
1
6.6
0
0
0
0
0

income-statement-row.row.interest-expense

0.741010.44.7
1.8
0
0
0
0
0
0

income-statement-row.row.selling-and-marketing-expenses

0---
-
-
-
-
-
-
-

income-statement-row.row.total-other-income-expensenet

-2.58-5.3-9.7-5
-1.4
6.6
4
0.8
0.1
-4.8
0

income-statement-row.row.ebitda-ratio-caps

0---
-
-
-
-
-
-
-

income-statement-row.row.other-operating-expenses

5.272.20-0.3
-0.5
6.6
4
0.9
0.2
0
0

income-statement-row.row.total-operating-expenses

-2.58-5.3-9.7-5
-1.4
6.6
4
0.8
0.1
-4.8
0

income-statement-row.row.interest-expense

0.741010.44.7
1.8
0
0
0
0
0
0

income-statement-row.row.depreciation-and-amortization

0.510.51.3-0.3
0.4
0.4
0.2
0.1
0.1
0
0

income-statement-row.row.ebitda-caps

-21.23---
-
-
-
-
-
-
-

income-statement-row.row.operating-income

-22.83-39.5-136.2-142.5
-96.5
-129
-89.3
-61
-30.4
-15.4
-6.7

income-statement-row.row.income-before-tax

-27.48-44.9-145.9-147.4
-97.8
-122.4
-85.3
-60.1
-30.3
-20.3
-6.7

income-statement-row.row.income-tax-expense

3.123.11.70.9
1.4
-0.4
4
0
0.1
4.9
0.5

income-statement-row.row.net-income

-30.59-48-147.6-148.4
-99.3
-122.1
-85.3
-60.1
-30.3
-20.3
-7.2
类似股票
您可能还对以下内容感兴趣：
SRNE
Sorrento Therapeutics, Inc..
0.014 USD
NASDAQ
MRVI
Maravai LifeSciences Holdings, Inc..
8.8 USD
NASDAQ
CMRA
Comera Life Sciences Holdings, Inc..
0.03 USD
NASDAQ
GUBRA.CO
Gubra A/S.
296 DKK
CPH
T5O.DE
CytoTools AG.
0.468 EUR
XETRA
HBC.OL
Hofseth BioCare ASA.
2.04 NOK
OSL
6826.HK
Shanghai Haohai Biological Technology Co., Ltd..
42.05 HKD
HKSE
PPBT
Purple Biotech Ltd..
0.67 USD
NASDAQ

常见问题

什么是 G1 Therapeutics, Inc. (GTHX) 总资产是多少？

G1 Therapeutics, Inc. (GTHX) 总资产为 121540000.000.

什么是企业年收入？

年收入为 29349000.000.

企业利润率是多少？

公司利润率为 0.919.

什么是公司自由现金流？

自由现金流为 -0.356.

什么是企业净利润率？

净利润率为 -0.364.

企业总收入是多少？

总收入为 -0.272.

什么是 G1 Therapeutics, Inc. (GTHX) 净利润？{{符号}}净利润（净收入）是多少？

净利润（净收入）为 -47967000.000.

公司总债务是多少？

债务总额为 57173000.000.

营业费用是多少？

运营支出为 114843000.000.

公司现金是多少？

企业现金为 19887000.000.